These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

502 related articles for article (PubMed ID: 6823136)

  • 1. The role of the activated clotting time in heparin administration and neutralization for cardiopulmonary bypass.
    Esposito RA; Culliford AT; Colvin SB; Thomas SJ; Lackner H; Spencer FC
    J Thorac Cardiovasc Surg; 1983 Feb; 85(2):174-85. PubMed ID: 6823136
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Detection of protamine and heparin after termination of cardiopulmonary bypass by thrombelastometry (ROTEM): results of a pilot study.
    Mittermayr M; Velik-Salchner C; Stalzer B; Margreiter J; Klingler A; Streif W; Fries D; Innerhofer P
    Anesth Analg; 2009 Mar; 108(3):743-50. PubMed ID: 19224778
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Activated clotting time for control of anticoagulation during surgery.
    Lefemine AA; Lewis M
    Am Surg; 1985 May; 51(5):274-8. PubMed ID: 3994170
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Heparin dosing and monitoring for cardiopulmonary bypass. A comparison of techniques with measurement of subclinical plasma coagulation.
    Gravlee GP; Haddon WS; Rothberger HK; Mills SA; Rogers AT; Bean VE; Buss DH; Prough DS; Cordell AR
    J Thorac Cardiovasc Surg; 1990 Mar; 99(3):518-27. PubMed ID: 2308370
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Management of postoperative heparin rebound following cardiopulmonary bypass.
    Pifarré R; Babka R; Sullivan HJ; Montoya A; Bakhos M; El-Etr A
    J Thorac Cardiovasc Surg; 1981 Mar; 81(3):378-81. PubMed ID: 7464201
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Monitoring activated clotting time for combined heparin and aprotinin application: in vivo evaluation of a new aprotinin-insensitive test using Sonoclot.
    Ganter MT; Monn A; Tavakoli R; Genoni M; Klaghofer R; Furrer L; Honegger H; Hofer CK
    Eur J Cardiothorac Surg; 2006 Aug; 30(2):278-84. PubMed ID: 16828293
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of two protocols for heparin neutralization by protamine after cardiopulmonary bypass.
    Arén C; Feddersen K; Rådegran K
    J Thorac Cardiovasc Surg; 1987 Oct; 94(4):539-41. PubMed ID: 3309479
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Heparin binding proteins. Contribution to heparin rebound after cardiopulmonary bypass.
    Teoh KH; Young E; Bradley CA; Hirsh J
    Circulation; 1993 Nov; 88(5 Pt 2):II420-5. PubMed ID: 8222188
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Heparin monitoring during cardiopulmonary bypass in congenital heart surgery].
    Isomatsu Y; Imai Y; Seo K; Terada M; Aoki M; Shin'oka T
    Kyobu Geka; 2000 Nov; 53(12):1001-4. PubMed ID: 11079303
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical experience with the activated clotting time for the control of heparin and protamine therapy during cardiopulmonary bypass.
    Akl BF; Vargas GM; Neal J; Robillard J; Kelly P
    J Thorac Cardiovasc Surg; 1980 Jan; 79(1):97-102. PubMed ID: 7350393
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The impact of heparin concentration and activated clotting time monitoring on blood conservation. A prospective, randomized evaluation in patients undergoing cardiac operation.
    Despotis GJ; Joist JH; Hogue CW; Alsoufiev A; Kater K; Goodnough LT; Santoro SA; Spitznagel E; Rosenblum M; Lappas DG
    J Thorac Cardiovasc Surg; 1995 Jul; 110(1):46-54. PubMed ID: 7609568
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Can extra protamine eliminate heparin rebound following cardiopulmonary bypass surgery?
    Teoh KH; Young E; Blackall MH; Roberts RS; Hirsh J
    J Thorac Cardiovasc Surg; 2004 Aug; 128(2):211-9. PubMed ID: 15282457
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Correlations between activated clotting time values and heparin concentration measurements in young infants undergoing cardiopulmonary bypass.
    Guzzetta NA; Monitz HG; Fernandez JD; Fazlollah TM; Knezevic A; Miller BE
    Anesth Analg; 2010 Jul; 111(1):173-9. PubMed ID: 20519414
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Activated coagulation and activated partial thromboplastin times in assessment and reversal of heparin-induced anticoagulation for cardiopulmonary bypass.
    Dauchot PJ; Berzina-Moettus L; Rabinovitch A; Ankeney JL
    Anesth Analg; 1983 Aug; 62(8):710-9. PubMed ID: 6869857
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of a heparin removal device in comparison with protamine after hypothermic cardiopulmonary bypass.
    Tao W; Deyo DJ; Brunston RL; Vertrees RA; Grochoske TL; Zwischenberger JB
    ASAIO J; 1997; 43(5):M825-30. PubMed ID: 9360162
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The relationship between heparin level and activated clotting time in the adult cardiac surgery population.
    Fitzgerald DJ; Patel A; Body SC; Garvin S
    Perfusion; 2009 Mar; 24(2):93-6. PubMed ID: 19654150
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prolonged Activated Clotting Time after Protamine Administration Does Not Indicate Residual Heparinization after Cardiopulmonary Bypass in Pediatric Open Heart Surgery.
    Yamamoto T; Wolf HG; Sinzobahamvya N; Asfour B; Hraska V; Schindler E
    Thorac Cardiovasc Surg; 2015 Aug; 63(5):397-403. PubMed ID: 26121380
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Heparin monitoring during cardiopulmonary bypass.
    Saleem A; Shenaq SS; Yawn DH; Harshberger K; Diemunsch P; Mohindra P
    Ann Clin Lab Sci; 1984; 14(6):474-9. PubMed ID: 6508227
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anticoagulation and anticoagulation reversal with cardiac surgery involving cardiopulmonary bypass: an update.
    Despotis GJ; Joist JH
    J Cardiothorac Vasc Anesth; 1999 Aug; 13(4 Suppl 1):18-29; discussion 36-7. PubMed ID: 10468245
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Control of temporary anticoagulation in extracorporeal circulation using activated coagulation time].
    Kessler G; Grünes G
    Anaesthesist; 1984 Dec; 33(12):588-91. PubMed ID: 6528961
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.